MA-VERISTAT
7.4.2021 14:02:07 CEST | Business Wire | Press release
Veristat , a scientific-minded, global clinical research organization (CRO), announced today that it transferred its majority ownership from Variance Development Partners to WindRose Health Investors (WindRose). WindRose invests exclusively in healthcare companies and has extensive experience across the healthcare services landscape, including outsourced biopharmaceutical services like Veristat’s.
“As a founder of Veristat, I believe that Veristat has attained the ideal investment partner who understands our philosophy, our values, and the impact we make in clinical research,” stated John P. Balser, Ph.D., President, Co-Founder, and Chief Statistical Officer of Veristat. “WindRose has a track record of successful collaboration, understands the critical nature of the scientific and therapeutic expertise we offer and will bring significant knowledge and a network of advisors to assist us as we continue to evolve.”
WindRose will support Veristat’s continued expansion to meet the needs of its growing client base around the world. This partnership will significantly benefit Veristat by complementing the leadership team with a group of diverse and knowledgeable healthcare advisors who share the same vision, culture, and focus on scientific excellence in clinical research.
“We are excited to enter into this relationship with Veristat,” said CJ Burnes, Partner with WindRose. “The Company’s clinical impact and scientific approach to partnering with companies advancing life-enhancing therapies is impressive. Their market position, stellar reputation, and leadership within biostatistics and ability to design and conduct complex clinical trials is unlike any other we have seen. In partnership with the management team and the founders, WindRose plans to contribute substantial resources to support the execution of Veristat’s strategy.”
“I am confident that our partnership with WindRose will allow Veristat’s continued focus on our core mission of helping sponsors solve the challenges that arise when developing ground-breaking products that improve and save lives through our differentiated approach to designing and executing clinical trials, clinical programs, regulatory submissions, and pharmacovigilance,” stated Patrick Flanagan, Chief Executive Officer of Veristat. “WindRose will provide us the capital and a deep network of relationships and expertise in the biotech and pharmaceutical industry as we strategically grow our company.”
Edgemont Partners acted as financial advisor to Veristat. Nutter McClennen & Fish LLP acted as legal advisor to Veristat, and McDermott Will & Emery LLP acted as legal advisor to WindRose.
About WindRose
WindRose makes equity investments in companies that operate within the services sectors of the healthcare industry. The firm focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. WindRose manages over $1.2 billion in investments and is currently investing out of its fifth fund. WindRose is based in New York City and invests in companies throughout the United States.
For more information, email WindRose at info@windrose.com .
About Veristat
Veristat , a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Rock-It Company Expands to Abu Dhabi, Strengthening the Capital’s Position as a Global Hub for Luxury, Culture, and Major Events11.7.2026 18:12:00 CEST | Press release
The Rock-It Company (Rock-It), one of the world’s leading providers of specialist logistics for time-critical and high-value sectors across live events and luxury goods, has expanded its footprint in the UAE to Abu Dhabi, in partnership with the Abu Dhabi Investment Office (ADIO). The expansion in the region brings Rock-It’s portfolio of renowned brands to the UAE capital to support Abu Dhabi’s vision of becoming a world-leading destination for luxury experiences, cultural attractions, and global events, while reinforcing the emirate’s position as a regional re-export hub and advanced logistics base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260710305177/en/ Through the collaboration, Rock-It seeks to develop world-class bonded storage and logistics facilities designed to serve the group’s five core end markets: sports, live entertainment, fine art, film & television, and luxury automotive. Once complete, Rock-It’s faci
L&T Technology Services Global EI Hackathon Sparks the Next Wave of AI-Native Engineering Solutions11.7.2026 13:35:00 CEST | Press release
Nearly 4,000 participants across 770+ teams from nine global locations became a part of the 24-hour innovation challenge L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services successfully concluded Engineering Intelligence (EI) OpenHack 2026, a first-of-its-kind global innovation challenge conducted simultaneously across nine locations spanning India, the U.S. and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260711573331/en/ LTTS Global EI OpenHack at the Munich office The hackathon brought together nearly 4,000 engineers (770+ teams) from Bengaluru, Mysuru, Chennai, Hyderabad, Pune, Vadodara, Mumbai, Dallas and Munich to tackle complex engineering challenges through AI-led innovation. More than 500 challenge statements were aligned with company’s strategic growth priorities, spanning Software Defined Mobility, Plant Buildout & Modernizati
Samos Energy Acquisition Corporation Announces Pricing of Initial Public Offering10.7.2026 15:32:00 CEST | Press release
Samos Energy Acquisition Corporation (the “Company”) announced today the pricing of its initial public offering (“IPO”) of 20,000,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “SAMO.U” beginning on July 10, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SAMO” and “SAMO.WS,” respectively. Cantor Fitzgerald & Co. is acting as the sole book running manager for the proposed offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units at the IPO price. The public offering is being made
Onera hPSG® Wins Prestigious Red Dot Product Design Award10.7.2026 15:00:00 CEST | Press release
Onera Health's patch-based home polysomnography solution, Onera hPSG®, was awarded the renowned ‘Red Dot Award: Product Design 2026’ in recognition of the sensors’ innovative design, advanced functionality, and user-centric engineering. Onera Health, a leader in transforming sleep medicine, announces that its innovative product, Onera hPSG®, has been honoured with the prestigious Red Dot Product Design Award for 2026. This international recognition celebrates exceptional design quality and underscores Onera Health's commitment to excellence, creativity, and patient-centric innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260710266668/en/ Onera Health's patch-based home polysomnography solution, Onera hPSG®, wins Prestigious Red Dot Product Design Award 2026. The Red Dot Award, one of the most sought-after seals of quality for good design, attracted thousands of entries from around the globe. Onera hPSG® stood out f
teamLab Biovortex Kyoto Welcomes Over 1 Million Visitors within 9 Months of Opening10.7.2026 09:00:00 CEST | Press release
teamLab Biovortex Kyoto has welcomed over 1 million visitors as of July 6, 2026, 9 months after its grand opening. (*1) These visitors arrived from more than 150 countries and regions. International visitors account for approximately 42% of the total. Many of these international visitors travel from distant countries and regions, including the United States, Australia, Canada, the United Kingdom, and Germany. Approximately 30% of these international visitors purchase their tickets at least 30 days in advance. teamLab Biovortex Kyoto is teamLab's largest museum in Japan, with an average visitor stay of over two and a half hours. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709913938/en/ teamLab Biovortex Kyoto Welcomes Over 1 Million Visitors within 9 Months of Opening *1 According to ticket purchase data from the official teamLab Biovortex Kyoto website (survey period: October 7, 2025 – July 6, 2026) Visitors Comment (M
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom